IBDEI1D2 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22685,1,4,0)
 ;;=4^E83.110
 ;;^UTILITY(U,$J,358.3,22685,2)
 ;;=^339602
 ;;^UTILITY(U,$J,358.3,22686,0)
 ;;=D47.3^^104^1056^6
 ;;^UTILITY(U,$J,358.3,22686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22686,1,3,0)
 ;;=3^Hemorrhagic Thrombocythemia,Essential
 ;;^UTILITY(U,$J,358.3,22686,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,22686,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,22687,0)
 ;;=D69.1^^104^1056^9
 ;;^UTILITY(U,$J,358.3,22687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22687,1,3,0)
 ;;=3^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,22687,1,4,0)
 ;;=4^D69.1
 ;;^UTILITY(U,$J,358.3,22687,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,22688,0)
 ;;=D69.6^^104^1056^10
 ;;^UTILITY(U,$J,358.3,22688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22688,1,3,0)
 ;;=3^Thrombocytopenia,Unspec
 ;;^UTILITY(U,$J,358.3,22688,1,4,0)
 ;;=4^D69.6
 ;;^UTILITY(U,$J,358.3,22688,2)
 ;;=^5002370
 ;;^UTILITY(U,$J,358.3,22689,0)
 ;;=I80.9^^104^1056^8
 ;;^UTILITY(U,$J,358.3,22689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22689,1,3,0)
 ;;=3^Phlebitis & Thrombophlebitis,Unspec Site
 ;;^UTILITY(U,$J,358.3,22689,1,4,0)
 ;;=4^I80.9
 ;;^UTILITY(U,$J,358.3,22689,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,22690,0)
 ;;=M31.1^^104^1056^11
 ;;^UTILITY(U,$J,358.3,22690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22690,1,3,0)
 ;;=3^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,22690,1,4,0)
 ;;=4^M31.1
 ;;^UTILITY(U,$J,358.3,22690,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,22691,0)
 ;;=D68.312^^104^1056^1
 ;;^UTILITY(U,$J,358.3,22691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22691,1,3,0)
 ;;=3^Antiphospholipid Antibody w/ Hemorrhagic Disorder
 ;;^UTILITY(U,$J,358.3,22691,1,4,0)
 ;;=4^D68.312
 ;;^UTILITY(U,$J,358.3,22691,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,22692,0)
 ;;=D68.318^^104^1056^5
 ;;^UTILITY(U,$J,358.3,22692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22692,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Circ Anticoag NEC
 ;;^UTILITY(U,$J,358.3,22692,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,22692,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,22693,0)
 ;;=D68.311^^104^1056^4
 ;;^UTILITY(U,$J,358.3,22693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22693,1,3,0)
 ;;=3^Hemophilia,Acquired
 ;;^UTILITY(U,$J,358.3,22693,1,4,0)
 ;;=4^D68.311
 ;;^UTILITY(U,$J,358.3,22693,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,22694,0)
 ;;=Z51.89^^104^1057^8
 ;;^UTILITY(U,$J,358.3,22694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22694,1,3,0)
 ;;=3^Specified Aftercare Encounter
 ;;^UTILITY(U,$J,358.3,22694,1,4,0)
 ;;=4^Z51.89
 ;;^UTILITY(U,$J,358.3,22694,2)
 ;;=^5063065
 ;;^UTILITY(U,$J,358.3,22695,0)
 ;;=Z51.11^^104^1057^1
 ;;^UTILITY(U,$J,358.3,22695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22695,1,3,0)
 ;;=3^Antineoplastic Chemotherapy Encounter
 ;;^UTILITY(U,$J,358.3,22695,1,4,0)
 ;;=4^Z51.11
 ;;^UTILITY(U,$J,358.3,22695,2)
 ;;=^5063061
 ;;^UTILITY(U,$J,358.3,22696,0)
 ;;=Z71.3^^104^1057^5
 ;;^UTILITY(U,$J,358.3,22696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22696,1,3,0)
 ;;=3^Dietary Counseling & Surveillance
 ;;^UTILITY(U,$J,358.3,22696,1,4,0)
 ;;=4^Z71.3
 ;;^UTILITY(U,$J,358.3,22696,2)
 ;;=^5063245
 ;;^UTILITY(U,$J,358.3,22697,0)
 ;;=Z31.5^^104^1057^6
 ;;^UTILITY(U,$J,358.3,22697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22697,1,3,0)
 ;;=3^Genetic Counseling
 ;;^UTILITY(U,$J,358.3,22697,1,4,0)
 ;;=4^Z31.5
 ;;^UTILITY(U,$J,358.3,22697,2)
 ;;=^5062838
 ;;^UTILITY(U,$J,358.3,22698,0)
 ;;=Z71.89^^104^1057^4
 ;;^UTILITY(U,$J,358.3,22698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22698,1,3,0)
 ;;=3^Counseling,Other Spec
 ;;^UTILITY(U,$J,358.3,22698,1,4,0)
 ;;=4^Z71.89
